Bortezomib in Treating Patients With Mantle Cell Lymphoma

NCT00030875 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NETWORK

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: bortezomib

Sponsor

NCIC Clinical Trials Group